Topline results from the large-scale Semaglutide Effects on Heart Disease and Stroke in Patients with Overweight or Obesity (SELECT) clinical study released today show that the Novo Nordisk obesity drug reduces the risk of major adverse cardiovascular events by 20 percent. The SELECT trial is the first to demonstrate the long-term cardiovascular benefits of an […]